Autologous Cell Therapy Market Size, Global Trends And Forecast to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Autologous Cell Therapy Market Size Analysis

Global Autologous Cell Therapy Market Introduction
By Cell Type
1. Introduction
  1. Cell Type By Value
2. Hematopoietic Stem Cells (HSCs)
  1. By Value
3. Mesenchymal Stem Cells (MSCs)
  1. By Value
4. Chondrocytes
  1. By Value
5. Fibroblasts
  1. By Value
6. Keratinocytes
  1. By Value
7. Other Autologous Cells
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Epidermis
  1. By Value
3. Bone Marrow
  1. By Value
4. Mesenchymal Stem Cells
  1. By Value
5. Haematopoietic Stem Cells
  1. By Value
6. Chondrocytes
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurodegenerative Disorders
  1. By Value
5. Autoimmune Disorders
  1. By Value
6. Orthopedics
  1. By Value
7. Wound Healing
  1. By Value
8. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Ambulatory Centers
  1. By Value
4. Academics & Research
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Cell Type
1. Introduction
  1. Cell Type By Value
2. Hematopoietic Stem Cells (HSCs)
  1. By Value
3. Mesenchymal Stem Cells (MSCs)
  1. By Value
4. Chondrocytes
  1. By Value
5. Fibroblasts
  1. By Value
6. Keratinocytes
  1. By Value
7. Other Autologous Cells
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Epidermis
  1. By Value
3. Bone Marrow
  1. By Value
4. Mesenchymal Stem Cells
  1. By Value
5. Haematopoietic Stem Cells
  1. By Value
6. Chondrocytes
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurodegenerative Disorders
  1. By Value
5. Autoimmune Disorders
  1. By Value
6. Orthopedics
  1. By Value
7. Wound Healing
  1. By Value
8. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Ambulatory Centers
  1. By Value
4. Academics & Research
  1. By Value
5. Others
  1. By Value
U.S.
1. By Cell Type
  1. Introduction
    1. Cell Type By Value
  2. Hematopoietic Stem Cells (HSCs)
    1. By Value
  3. Mesenchymal Stem Cells (MSCs)
    1. By Value
  4. Chondrocytes
    1. By Value
  5. Fibroblasts
    1. By Value
  6. Keratinocytes
    1. By Value
  7. Other Autologous Cells
    1. By Value
2. By Source
  1. Introduction
    1. Source By Value
  2. Epidermis
    1. By Value
  3. Bone Marrow
    1. By Value
  4. Mesenchymal Stem Cells
    1. By Value
  5. Haematopoietic Stem Cells
    1. By Value
  6. Chondrocytes
    1. By Value
  7. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Cancer
    1. By Value
  3. Cardiovascular Disorders
    1. By Value
  4. Neurodegenerative Disorders
    1. By Value
  5. Autoimmune Disorders
    1. By Value
  6. Orthopedics
    1. By Value
  7. Wound Healing
    1. By Value
  8. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Ambulatory Centers
    1. By Value
  4. Academics & Research
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Cell Type
1. Introduction
  1. Cell Type By Value
2. Hematopoietic Stem Cells (HSCs)
  1. By Value
3. Mesenchymal Stem Cells (MSCs)
  1. By Value
4. Chondrocytes
  1. By Value
5. Fibroblasts
  1. By Value
6. Keratinocytes
  1. By Value
7. Other Autologous Cells
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Epidermis
  1. By Value
3. Bone Marrow
  1. By Value
4. Mesenchymal Stem Cells
  1. By Value
5. Haematopoietic Stem Cells
  1. By Value
6. Chondrocytes
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurodegenerative Disorders
  1. By Value
5. Autoimmune Disorders
  1. By Value
6. Orthopedics
  1. By Value
7. Wound Healing
  1. By Value
8. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Ambulatory Centers
  1. By Value
4. Academics & Research
  1. By Value
5. Others
  1. By Value
U.K.
1. By Cell Type
  1. Introduction
    1. Cell Type By Value
  2. Hematopoietic Stem Cells (HSCs)
    1. By Value
  3. Mesenchymal Stem Cells (MSCs)
    1. By Value
  4. Chondrocytes
    1. By Value
  5. Fibroblasts
    1. By Value
  6. Keratinocytes
    1. By Value
  7. Other Autologous Cells
    1. By Value
2. By Source
  1. Introduction
    1. Source By Value
  2. Epidermis
    1. By Value
  3. Bone Marrow
    1. By Value
  4. Mesenchymal Stem Cells
    1. By Value
  5. Haematopoietic Stem Cells
    1. By Value
  6. Chondrocytes
    1. By Value
  7. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Cancer
    1. By Value
  3. Cardiovascular Disorders
    1. By Value
  4. Neurodegenerative Disorders
    1. By Value
  5. Autoimmune Disorders
    1. By Value
  6. Orthopedics
    1. By Value
  7. Wound Healing
    1. By Value
  8. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Ambulatory Centers
    1. By Value
  4. Academics & Research
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Cell Type
1. Introduction
  1. Cell Type By Value
2. Hematopoietic Stem Cells (HSCs)
  1. By Value
3. Mesenchymal Stem Cells (MSCs)
  1. By Value
4. Chondrocytes
  1. By Value
5. Fibroblasts
  1. By Value
6. Keratinocytes
  1. By Value
7. Other Autologous Cells
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Epidermis
  1. By Value
3. Bone Marrow
  1. By Value
4. Mesenchymal Stem Cells
  1. By Value
5. Haematopoietic Stem Cells
  1. By Value
6. Chondrocytes
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurodegenerative Disorders
  1. By Value
5. Autoimmune Disorders
  1. By Value
6. Orthopedics
  1. By Value
7. Wound Healing
  1. By Value
8. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Ambulatory Centers
  1. By Value
4. Academics & Research
  1. By Value
5. Others
  1. By Value
China
1. By Cell Type
  1. Introduction
    1. Cell Type By Value
  2. Hematopoietic Stem Cells (HSCs)
    1. By Value
  3. Mesenchymal Stem Cells (MSCs)
    1. By Value
  4. Chondrocytes
    1. By Value
  5. Fibroblasts
    1. By Value
  6. Keratinocytes
    1. By Value
  7. Other Autologous Cells
    1. By Value
2. By Source
  1. Introduction
    1. Source By Value
  2. Epidermis
    1. By Value
  3. Bone Marrow
    1. By Value
  4. Mesenchymal Stem Cells
    1. By Value
  5. Haematopoietic Stem Cells
    1. By Value
  6. Chondrocytes
    1. By Value
  7. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Cancer
    1. By Value
  3. Cardiovascular Disorders
    1. By Value
  4. Neurodegenerative Disorders
    1. By Value
  5. Autoimmune Disorders
    1. By Value
  6. Orthopedics
    1. By Value
  7. Wound Healing
    1. By Value
  8. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Ambulatory Centers
    1. By Value
  4. Academics & Research
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Cell Type
1. Introduction
  1. Cell Type By Value
2. Hematopoietic Stem Cells (HSCs)
  1. By Value
3. Mesenchymal Stem Cells (MSCs)
  1. By Value
4. Chondrocytes
  1. By Value
5. Fibroblasts
  1. By Value
6. Keratinocytes
  1. By Value
7. Other Autologous Cells
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Epidermis
  1. By Value
3. Bone Marrow
  1. By Value
4. Mesenchymal Stem Cells
  1. By Value
5. Haematopoietic Stem Cells
  1. By Value
6. Chondrocytes
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurodegenerative Disorders
  1. By Value
5. Autoimmune Disorders
  1. By Value
6. Orthopedics
  1. By Value
7. Wound Healing
  1. By Value
8. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Ambulatory Centers
  1. By Value
4. Academics & Research
  1. By Value
5. Others
  1. By Value
UAE
1. By Cell Type
  1. Introduction
    1. Cell Type By Value
  2. Hematopoietic Stem Cells (HSCs)
    1. By Value
  3. Mesenchymal Stem Cells (MSCs)
    1. By Value
  4. Chondrocytes
    1. By Value
  5. Fibroblasts
    1. By Value
  6. Keratinocytes
    1. By Value
  7. Other Autologous Cells
    1. By Value
2. By Source
  1. Introduction
    1. Source By Value
  2. Epidermis
    1. By Value
  3. Bone Marrow
    1. By Value
  4. Mesenchymal Stem Cells
    1. By Value
  5. Haematopoietic Stem Cells
    1. By Value
  6. Chondrocytes
    1. By Value
  7. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Cancer
    1. By Value
  3. Cardiovascular Disorders
    1. By Value
  4. Neurodegenerative Disorders
    1. By Value
  5. Autoimmune Disorders
    1. By Value
  6. Orthopedics
    1. By Value
  7. Wound Healing
    1. By Value
  8. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Ambulatory Centers
    1. By Value
  4. Academics & Research
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Cell Type
1. Introduction
  1. Cell Type By Value
2. Hematopoietic Stem Cells (HSCs)
  1. By Value
3. Mesenchymal Stem Cells (MSCs)
  1. By Value
4. Chondrocytes
  1. By Value
5. Fibroblasts
  1. By Value
6. Keratinocytes
  1. By Value
7. Other Autologous Cells
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Epidermis
  1. By Value
3. Bone Marrow
  1. By Value
4. Mesenchymal Stem Cells
  1. By Value
5. Haematopoietic Stem Cells
  1. By Value
6. Chondrocytes
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurodegenerative Disorders
  1. By Value
5. Autoimmune Disorders
  1. By Value
6. Orthopedics
  1. By Value
7. Wound Healing
  1. By Value
8. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Ambulatory Centers
  1. By Value
4. Academics & Research
  1. By Value
5. Others
  1. By Value
Brazil
1. By Cell Type
  1. Introduction
    1. Cell Type By Value
  2. Hematopoietic Stem Cells (HSCs)
    1. By Value
  3. Mesenchymal Stem Cells (MSCs)
    1. By Value
  4. Chondrocytes
    1. By Value
  5. Fibroblasts
    1. By Value
  6. Keratinocytes
    1. By Value
  7. Other Autologous Cells
    1. By Value
2. By Source
  1. Introduction
    1. Source By Value
  2. Epidermis
    1. By Value
  3. Bone Marrow
    1. By Value
  4. Mesenchymal Stem Cells
    1. By Value
  5. Haematopoietic Stem Cells
    1. By Value
  6. Chondrocytes
    1. By Value
  7. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Cancer
    1. By Value
  3. Cardiovascular Disorders
    1. By Value
  4. Neurodegenerative Disorders
    1. By Value
  5. Autoimmune Disorders
    1. By Value
  6. Orthopedics
    1. By Value
  7. Wound Healing
    1. By Value
  8. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Ambulatory Centers
    1. By Value
  4. Academics & Research
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Autologous Cell Therapy Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Vericel Corporation
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
BrainStorm Cell Therapeutics Inc.
Holostem Terapie Avanzate S.r.l.
Takeda Pharmaceutical Company Limited
DON AG
BioTime, Inc. (now Lineage Cell Therapeutics)
Castle Creek Biosciences, Inc.
Iovance Biotherapeutics, Inc.
Regeneus Ltd
Celgene Corporation (a Bristol-Myers Squibb company)
Novartis AG
Pharmicell Co., Ltd.
Medipost Co., Ltd.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment